Changes are happening with the Zatolmilast clinical trials for Fragile X syndrome. The studies previously known as the Tetra trials are now called the EXPERIENCE clinical studies — a name that reflects the goal of further evaluating the safety and efficacy of an investigational study drug on cognition and other aspects of Fragile X syndrome. Now led by Shionogi, these Phase 2b/3 clinical trials are still enrolling males aged 9-45 across the U.S. who meet the eligibility criteria. Participants who complete the placebo-controlled study may have the opportunity to continue treatment in an open-label extension. Learn more about the study and find clinical trial sites through FRAXA: ?? https://lnkd.in/epfe68_6
